Neuphoria Therapeutics ratios data for the quarter ended Mar 2026. These financial ratios cover 14 quarters of results from Jun 2021 through Mar 2026, standardized by Business Quant from the company’s SEC filings.
| Ratios | Jun2021 | Jun2022 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||||||
| EBT Margin | -291.49% | 74.54% | 116,256.64% | |||||||||||
| EBIT Margin | -558.84% | 79.85% | 43,981.65% | |||||||||||
| EBITDA Margin | -558.84% | 79.85% | 43,981.65% | |||||||||||
| Operating Margin | -558.84% | 79.85% | 43,981.65% | |||||||||||
| Net Margin | -293.24% | 75.08% | 114,247.12% | |||||||||||
| FCF Margin | -506.72% | 76.36% | 26,850.85% | |||||||||||
| Efficiency | ||||||||||||||
| Assets AverageAssets Avg. | 21.25M | 44.28M | 37.76M | 25.28M | 20.54M | 24.44M | 29.65M | 27.97M | 31.97M | 35.70M | ||||
| Valuation | ||||||||||||||
| Price to EarningsP/E | -738.05 | -486.12 | -554.62 | 0.00M | -816.32 | -220.03 | 63.76 | -58.39 | -148.36 | 259.48 | -0.00M | |||
| Price to SalesP/S | 645.21 | 47.87 | -0.07M | |||||||||||
| Price to BookP/B | 232.05 | 147.63 | 234.45 | 113.55 | 85.86 | 65.57 | 38.49 | 31.10 | 27.62 | 46.58 | 117.48 | 16.29 | 17.24 | |
| Enterprise Value | 9,435.50M | 3,258.49M | 4,030.89M | 2,203.83M | 1,532.39M | 1,134.28M | 648.88M | 423.24M | 701.00M | 870.81M | 1,456.03M | 461.41M | 487.93M | |
| EV to EBIT | -737.23 | -484.05 | -640.09 | -207.06 | -181.88 | -114.28 | 58.53 | -149.24 | -257.58 | -113.62 | -402.70 | |||
| EV to EBITDA | -737.23 | -484.05 | -640.09 | -207.06 | -181.88 | -114.28 | 58.53 | -149.24 | -257.58 | -113.62 | -402.70 | |||
| Market Capitalization | 9,459.54M | 3,270.69M | 4,039.03M | 2,213.98M | 1,540.81M | 1,146.88M | 656.96M | 427.59M | 718.05M | 885.09M | 1,469.76M | 483.69M | 507.37M | |
| Price to FCFP/FCF | -911.79 | -561.19 | -467.61 | -380.92 | -148.20 | -127.33 | 62.69 | -248.46 | -386.78 | -75.22 | -150.58 | |||
| EV to FCF | -909.95 | -558.62 | -465.06 | -376.74 | -146.37 | -126.04 | 61.20 | -244.45 | -383.17 | -71.75 | -144.81 | |||
| EV to CFO | -909.95 | -558.62 | -465.06 | -376.74 | -146.37 | -126.04 | 61.20 | -244.45 | -383.17 | -71.75 | -144.81 | |||
| Return Ratios | ||||||||||||||
| Return on Sales [ROS]ROS | -558.84% | 79.85% | 43,981.65% | |||||||||||
| Return on Capital Employed [ROCE]ROCE | -70.35% | -82.26% | -3.37% | -4.44% | -14.07% | -12.15% | -49.02% | |||||||
| Return on Assets [ROA]ROA | -27.75% | -21.45% | 39.42% | -22.40% | -56.30% | -37.34% | -66.39% |